Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gentry Haughton

Podiatrist, Foot & Ankle Surgery Shreveport, LA Doctor of Podiatric Medicine

NPI 1316171358 CMS profile 485714

592 Unadilla St, Shreveport, LA 71106

Open in the dashboard

General payments

$9,719

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gentry Haughton of Shreveport, LA is reported in the CMS Open Payments database as having received $9,719 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,171 29
2024 General $3,119 44
2023 General $1,236 27
2022 General $1,637 40
2021 General $1,187 40
2020 General $525 26
2019 General $844 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gentry Haughton
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Gentry Haughton were reported at $1,171. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Gentry Haughton Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $844 $389 $118–$1,406 $163
2020 $525 $191 $62–$691 $114
2021 $1,187 $329 $104–$1,341 $132
2022 $1,637 $419 $125–$1,611 $149
2023 $1,236 $377 $128–$1,164 $160
2024 $3,119 $394 $134–$1,168 $164
2025 $1,171 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $2,912 30 payments
  2. Organogenesis Inc. $2,070 54 payments
  3. Melinta Therapeutics, Inc. $1,493 31 payments
  4. AbbVie, Inc. $1,461 74 payments
  5. Kerecis Limited $723 5 payments
  6. Paratek Pharmaceuticals, Inc. $492 5 payments
  7. Allergan Inc. $344 25 payments
  8. Smith+Nephew, Inc. $124 1 payment
  9. Integra LifeSciences Corporation $50 3 payments
  10. MIMEDX Group, Inc. $18 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,258 227 payments
  2. Travel and Lodging $1,462 4 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $2,826 29 payments
  2. DALVANCE $1,799 98 payments
  3. Puraply $1,373 36 payments
  4. Kimyrsa $806 15 payments
  5. Orbactiv $565 18 payments
  6. Kerecis Omega3 SurgiClose $541 2 payments
  7. Kerecis Omega3 GraftGuide $541 2 payments
  8. Puraply Antimicrobial $494 13 payments
  9. NUZYRA $492 5 payments
  10. Kerecis Omega3 Marigen $304 1 payment
  11. Other $4,216 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,831

Median for Podiatry: 160

Drug cost

$28,181

Median for Podiatry: $2,368

Branded share of claims

0.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 262 $8,088
Gabapentin Generic 619 $5,323
Clobetasol Propionate Generic 60 $4,870
Terbinafine Hcl Generic 414 $3,805
Duloxetine Hcl Generic 206 $3,222
Diclofenac Sodium Generic 26 $1,053
Doxycycline Hyclate Generic 69 $656
Meloxicam Generic 108 $394
Clotrimazole Generic 18 $295
Fluconazole Generic 11 $213

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$63,297

Medicare's payments for the services billed

Medicare patients

407

Average age 77

Services billed

1,247

224 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Depression 58%
Alzheimer's or dementia 58%
Arthritis 52%
Chronic kidney disease 41%
Ischemic heart disease 40%
Heart failure 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $278
$278 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $137
$137 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $125
$125 — —
TEFLARO
  • AbbVie, Inc. $24
$24 — —
Orbactiv
  • Melinta Therapeutics, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record